Alcohol septal ablation for hypertrophic cardiomyopathy: Indications and technique

Catheterization and Cardiovascular Interventions

Volumn 66, Issue 3, 2005, Pages 375-389

  Holmes Jr , David R ^a   Valeti, Uma S ^a   Nishimura, Rick A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Heart septum; Left ventricular outflow obstruction; Myocardial disease

Indexed keywords

ALCOHOL; CONTRAST MEDIUM;

ALCOHOL SEPTAL ABLATION; ANGIOGRAPHY; ARTERY DIAMETER; CONTRAST ENHANCEMENT; ECHOCARDIOGRAPHY; HEART CATHETERIZATION; HEART HEMODYNAMICS; HEART LEFT VENTRICLE OUTFLOW TRACT OBSTRUCTION; HEART MUSCLE CONDUCTION DISTURBANCE; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE SEPTUM; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; PATIENT SELECTION; PRACTICE GUIDELINE; REVIEW;

CARDIOMYOPATHY, HYPERTROPHIC; ETHANOL; HEART SEPTUM; HUMANS; INJECTIONS, INTRALESIONAL; TREATMENT OUTCOME;

EID: 27644505168     PISSN: 15221946     EISSN: None     Source Type: Journal    
DOI: 10.1002/ccd.20500     Document Type: Review

References (34)

1. Morrow AG, Roberts WC, Ross J Jr, Fisher RD, Behrendt DM, Mason DT, Braunwald E. Obstruction to left ventricular outflow: current concepts of management and operative treatment. Ann Intern Med 1968;69:1255-1286.
2. Tajik AJ, Giuliani ER, Weidman WH, Brandenburg RO, McGoon DC. Idiopathic hypertrophic subaortic stenosis: long-term surgical follow-up. Am J Cardiol 1974;34:815-822.
3. Morrow AG, Reitz BA, Epstein SE, Henry WL, Conkle DM, Itscoitz SB, Redwood DR. Operative treatment in hypertrophic subaortic stenosis: techniques, and the results of pre and post-operative assessments in 83 patients. Circulation 1975;52:88-102.
4. Beahrs MM, Tajik AJ, Seward JB, Giuliani ER, McGoon DC. Hypertrophic obstructive cardiomyopathy: ten- to 21-year follow-up after partial septal myectomy. Am J Cardiol 1983;51:1160-1166.
5. McCully RB, Nishimura RA, Tajik AJ, Schaff HV, Danielson GK. Extent of clinical improvement after surgical treatment of hypertrophic obstructive cardiomyopathy. Circulation 1996;94:467-471.
6. Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 1995;346:211-214.
7. Veselka J, Honek T. Early remodelling of left ventricle and improvement of myocardial performance in patients after percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy. Int J Cardiol 2003;88:27-32.
8. Bhagwandeen R, Woo A, Ross J, Wigle ED, Rakowski H, Kwinter J, Eriksson MJ, Schwartz L. Septal ethanol ablation for hypertrophic obstructive cardiomyopathy: early and intermediate results of a Canadian referral centre. Can J Cardiol 2003;19:912-917.
9. Nagueh SF, Ommen SR, Lakkis NM, Killip D, Zoghbi WA, Schaff HV, Danielson GK, Quinones MA, Tajik AJ, Spencer WH III. Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 2001;38:1701-1706.
10. Mazur W, Nagueh SF, Lakkis NM, Middleton KJ, Killip D, Roberts R, Spencer WH III. Regression of left ventricular hypertrophy after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Circulation 2001;103:1492-1496.
11. Lakkis N, Plana JC, Nagueh S, Killip D, Roberts R, Spencer WH III. Efficacy of nonsurgical septal reduction therapy in symptomatic patients with obstructive hypertrophic cardiomyopathy and provocable gradients. Am J Cardiol 2001;88:583-586.
12. Seggewiss H. Percutaneous transluminal septal myocardial ablation: a new treatment for hypertrophic obstructive cardiomyopathy. Eur Heart J 2000;21:704-707.
13. Tsuchikane E, Takeda Y, Kobayashi T, Yachiku K, Nasu K, Kobayashi Y, Matsumoto H, Awata N. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy. Circ J 2003;67:763-767.
14. Kuhn H. Transcoronary ablation of septal hypertrophy (TASH): a 5-year experience. Z Kardiol 2000;89:559-564.
15. Knight C, Kurbaan AS, Seggewiss H, Henein M, Gunning M, Harrington D, Fassbender D, Gleichmann U, Sigwart U. Nonsurgical septal reduction for hypertrophic obstructive cardiomyopathy: outcome in the first series of patients. Circulation 1997;95:2075-2081.
16. Faber L, Ziemssen P, Seggewiss H. Targeting percutaneous transluminal septal ablation for hypertrophic obstructive cardiomyopathy by intraprocedural echocardiographic monitoring. J Am Soc Echocardiogr 2000;13:1074-1079.
17. Faber L, Meissner A, Ziemssen P, Seggewiss H. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: long term follow up of the first series of 25 patients. Heart 2000;83:326-331.
18. van Dockum WG, ten Cate FJ, ten Berg JM, Beek AM, Twisk JW, Vos J, Hofman MB, Visser CA, van Rossum AC. Myocardial infarction after percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: evaluation by contrast-enhanced magnetic resonance imaging. J Am Coll Cardiol 2004;43:27-34.
19. Seggewiss H, Faber L, Gleichmann U. Percutaneous transluminal septal ablation in hypertrophic obstructive cardiomyopathy. Thorac Cardiovasc Surg 1999;47:94-100.
20. Faber L, Seggewiss H, Ziemssen P, Gleichmann U. Intraprocedural myocardial contrast echocardiography as a routine procedure in percutaneous transluminal septal myocardial ablation: detection of threatening myocardial necrosis distant from the septal target area. Catheter Cardiovasc Interv 1999;47:462-466.
21. Sigwart U. Non-surgical myocardial ablation: for hypertrophic obstructive cardiomyopathy. Cardiologia 1998;43:157-161.
22. Seggewiss H, Gleichmann U, Faber L, Fassbender D, Schmidt HK, Strick S. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results and 3-month follow-up in 25 patients. J Am Coll Cardiol 1998;31:252-258.
23. Nagueh SF, Lakkis NM, He ZX, Middleton KJ, Killip D, Zoghbi WA, Quinones MA, Roberts R, Verani MS, Kleiman NS, Spencer WH III. Role of myocardial contrast echocardiography during nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 1998;32:225-229.
24. Lakkis NM, Nagueh SF, Kleiman NS, Killip D, He ZX, Verani MS, Roberts R, Spencer WH III. Echocardiography-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy. Circulation 1998;98:1750-1755.
25. Faber L, Seggewiss H, Gleichmann U. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: results with respect to intraprocedural myocardial contrast echocardiography. Circulation 1998;98:2415-2421.
26. Li ZQ, Cheng TO, Zhang WW, Qiao SB, Zhao LY, Jin YZ, Guan RM, Liu L. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: the Chinese experience in 119 patients from a single center. Int J Cardiol 2004;93:197-202.
27. Chang SM, Lakkis NM, Franklin J, Spencer WH III, Nagueh SF. Predictors of outcome after alcohol septal ablation therapy in patients with hypertrophic obstructive cardiomyopathy. Circulation 2004;109:824-827.
28. Nagueh SF, Lakkis NM, Middleton KJ, Killip D, Zoghbi WA, Quinones MA, Spencer WH III. Changes in left ventricular filling and left atrial function six months after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 1999;34:1123-1128.
29. Kuhn H, Seggewiss H, Gietzen FH, Boekstegers P, Neuhaus L, Seipel L. Catheter-based therapy for hypertrophic obstructive cardiomyopathy: first in-hospital outcome analysis of the German TASH registry. Z Kardiol 2004;93:23-31.
30. Nielsen CD, Killip D, Spencer WH III. Nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy: short-term results in 50 consecutive procedures. Clin Cardiol 2003;26:275-279.
31. Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn JH, Seidman CE, Shah PM, Spencer WH III, Spirito P, Ten Cate FJ, Wigle ED, Vogel RA, Abrams J, Bates ER, Brodie BR, Danias PG, Gregoratos G, Hlatky MA, Hochman JS, Kaul S, Lichtenberg RC, Lindner JR, O'Rourke RA, Pohost GM, Schofield RS, Tracy CM, Winters WL Jr, Klein WW, Priori SG, Alonso-Garcia A, Blomstrom-Lundqvist C, De Backer G, Deckers J, Flather M, Hradec J, Oto A, Parkhomenko A, Silber S, Torbicki A, Task Force on Clinical Expert Consensus Documents, American College of Cardiology, Committee for Practice Guidelines, European Society of Cardiology. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 2003;42:1687-1713.
32. Chang SM, Nagueh SF, Spencer WH III, Lakkis NM. Complete heart block: determinants and clinical impact in patients with hypertrophic obstructive cardiomyopathy undergoing nonsurgical septal reduction therapy. J Am Coll Cardiol 2003;42:296-300.
33. Singh M, Edwards WD, Holmes DR Jr, Tajik AJ, Nishimura RA. Anatomy of the first septal perforating artery: a study with implications for ablation therapy for hypertrophic cardiomyopathy. Mayo Clin Proc 2001;76:799-802.
34. Faber L, Seggewiss H, Welge D, Fassbender D, Ziemssen P, Schmidt HK, Gleichmann U, Horstkotte D. Predicting the risk of atrioventricular conduction lesions after percutaneous septal ablation for obstructive hypertrophic cardiomyopathy. Z Kardiol 2003;92:39-47.